Abstract:

Objective To explore the efficacy and safety of tofatib citrate in the treatment of active anky⁃ lost spondylitis（AS）. Methods A total of 90 patients with active AS hospitalized in our hospital from January 2017 to January 2021 were included and were equally divided into control group and observation group using the random number table method. The patients in the control group received routine treatment for active AS，and those in the observation group were treated with tofatib citrate in addition to the routine treatment regimen as in the control group，and the efficacy was evaluated after continuous treatment for 3 courses. The two groups were com⁃ pared in terms of the scores by Bath Ankylosing spondylitis function Index（BASFI），Bath Ankylosing spondylitis measurement Index（BASMI），total back pain scoring and Jenkins Sleep Assessment Questionnaire（JSEQ），the levels of c⁃reactive protein（CRP）and ESR in peripheral blood，the overall efficacy grades and the occurrence of treatment ⁃ related adverse reactions. Results After 3 courses of treatment，the BASFI，BASMI，VAS and JSEQ scores of the observation group were all significantly lower than those of the control group（P < 0.05）. The levels of CRP and ESR in the observation group were significantly lower than those in the control group（P < 0.05）. The total effective rate in the observation group was significantly higher than that in the control group（P < 0.05）. There was no statistical significance in the occurrence of treatment⁃related adverse reactions between the two groups（P > 0.05）. Conclusion Tofatib citrate can effectively optimize the condition and improve the efficacy in the treatment of active AS with good safety. 

Key words:

active ankylosing spondylitis, tofatib citrate, therapeutic effect, security